Stock Screener App

무료 -

설치하다

1.53

1.29% -0.02

Ovid Therapeutics Inc (OVID)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측

Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스

Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease - simplywall.st

Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots - Seeking Alpha

Gains Report: Will Ionis Pharmaceuticals Inc benefit from sector rotation2025 Retail Activity & Growth Focused Investment Plans - baoquankhu1.vn

Does Ovid Therapeutics Inc. have declining or rising EPSWeekly Trend Report & Weekly Stock Breakout Alerts - mfd.ru

Why Ovid Therapeutics Inc. (1OT) stock stays on top picksTrading Volume Trends & Use Time as Your Investing Ally - bollywoodhelpline.com

Investment Recap: Will Ovid Therapeutics Inc announce a stock splitEntry Point & Expert Curated Trade Ideas - baoquankhu1.vn

What is the target price for Ovid Therapeutics Inc. stockQuarterly Trade Summary & Weekly Top Gainers Alerts - bollywoodhelpline.com

Sectors Review: Is Ovid Therapeutics Inc stock risky to hold now2025 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn

Risk Hedge: Will BMBL benefit from AI trends2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn

Why is Ovid Therapeutics Inc stock going upEarnings Risk Summary & Low Drawdown Trading Techniques - baoquankhu1.vn

Can Ovid Therapeutics Inc. (1OT) stock sustain breakout momentumJuly 2025 Summary & Fast Exit/Entry Strategy Plans - bollywoodhelpline.com

Aug Analyst Calls: What risks investors should watch in Ovid Therapeutics Inc stockWeekly Trading Summary & Verified Technical Signals - Bộ Nội Vụ

Market Review: Does Ovid Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn

How Ovid Therapeutics Inc. stock performs in weak economyMarket Growth Review & Accurate Entry/Exit Alerts - Улправда

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Published on: 2026-01-09 08:22:12 - Улправда

Is Ovid Therapeutics Inc. (1OT) stock safe for risk averse investorsWeekly Trade Report & Real-Time Volume Trigger Notifications - Улправда

Why hedge funds are buying Ovid Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - Улправда

Can Ovid Therapeutics Inc. stock hit record highs againQuarterly Investment Review & Weekly Consistent Profit Watchlists - Улправда

Will Ovid Therapeutics Inc. stock benefit from upcoming earnings reports2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда

Aug Spikes: Can Ovid Therapeutics Inc 1OT stock sustain breakout momentumEarnings Overview Report & Safe Capital Growth Stock Tips - Bộ Nội Vụ

How Ovid Therapeutics Inc. stock reacts to oil prices2026 world cup usa national team qualification goalkeepers low block defense knockout prediction statistical analysis - ulpravda.ru

Ovid Therapeutics (OVID) Price Target Increased by 22.06% to 4.23 - MSN

Is Ovid Therapeutics Inc. stock positioned well for digital economy2026 world cup usa national team round of 32 defensive leaders low block defense group prediction preview - ulpravda.ru

Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN

OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Ovid Therapeutics is a buy, this analyst says - Cantech Letter

Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold" - MarketBeat

Ovid Therapeutics (STU:1OT) EV-to-FCF : -2.91 (As of Dec. 26, 2025) - GuruFocus

Ovid Therapeutics (STU:1OT) EV-to-OCF : -2.91 (As of Dec. 27, 2025) - GuruFocus

Promising Penny Stocks To Watch In December 2025 - simplywall.st

FY2025 Earnings Forecast for OVID Issued By Lifesci Capital - MarketBeat

LifeSci Capital Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq

Form 424B3 Ovid Therapeutics Inc. - StreetInsider

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Ovid Therapeutics (OVID) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital - MarketBeat

Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

OVID: HC Wainwright Reiterates Buy Rating with $2.00 Price Targe - GuruFocus

HC Wainwright & Co. Reiterates Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq

Is Ovid Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда

How Ovid Therapeutics Inc. (1OT) stock stacks up against competitorsWeekly Trade Report & Smart Investment Allocation Insights - Улправда

Will Ovid Therapeutics Inc. stock recover faster than peersGold Moves & Real-Time Volume Triggers - DonanımHaber

Is Ovid Therapeutics Inc. stock a smart buy before Fed meetingWatch List & Safe Entry Trade Reports - Улправда

Ovid Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis

Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy - Citeline News & Insights

Ovid’s KCC2 activator shows promising safety in early trial By Investing.com - Investing.com Nigeria

Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data - TipRanks

Ovid Therapeutics announces phase 1 results for Ov350 - marketscreener.com

Ovid Therapeutics Inc Reports Phase 1 Results for OV350 - TradingView — Track All Markets

Ovid’s KCC2 activator shows promising safety in early trial - Investing.com

Ovid Therapeutics Reports Phase 1 Results for the - GlobeNewswire

RVMD

$98.87

0.80%

INCY

$100.87

0.01%

GMAB

$32.73

2.01%

BNTX

$116.66

0.09%

INSM

$157.55

0.22%

ONC

$346.55

1.10%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개